FDA production approval for a drug is expensive. If a competitor pays and gets a new line approved, the prize is zero, because of competition from the other li

FDA production approval for a drug is expensive. If a competitor pays and gets a new line approved, the prize is zero, because of competition from the other line. If no competitor pays the prize is almost unlimited, because of no competition. The government or a charity should fund another line, and should in general provide incentives to companies to not shut down existing approved lines if it would leave only one company standing.